# Dossier: ORA BIOMEDICAL, INC.

## SBIR Award Details

**Award Title:** N/A

**Amount:** $74,766.00

**Award Date:** 2024-05-17

**Branch:** USAF

## AI-Generated Intelligence Summary

**Company Overview:**

ORA Biomedical, Inc. (ORA) focuses on developing advanced medical solutions designed to enhance warfighter survivability and operational effectiveness. Their primary business is the creation of technologies for rapid, point-of-injury blood stabilization and resuscitation, specifically addressing the critical need to minimize blood loss and improve outcomes in austere environments where immediate access to blood transfusions is unavailable. ORA aims to solve the problem of preventable deaths due to hemorrhage, particularly in combat scenarios and remote locations. Their unique value proposition lies in their innovative approach to freeze-dried plasma and other hemostatic agents that can be rapidly reconstituted and administered on-site, thereby bridging the gap between the point of injury and definitive medical care.

**Technology Focus:**

* Freeze-Dried Plasma (FDP):\*\* ORA is developing shelf-stable, freeze-dried plasma that can be easily reconstituted with sterile water or saline solution in minutes, providing a readily available source of vital clotting factors to stop bleeding. They are working towards FDA approval for field use.
* Advanced Hemostatic Agents:\*\* ORA is researching and developing novel hemostatic agents designed to augment FDP’s effects and further enhance blood clotting at the point of injury, potentially including biocompatible materials and targeted drug delivery systems.

**Recent Developments & Traction:**

* $4.9M Funding from the US Army Medical Research and Development Command (USAMRDC):\*\* In late 2023, ORA Biomedical secured $4.9 million in funding from the US Army Medical Research and Development Command (USAMRDC) to advance the development and clinical testing of its freeze-dried plasma product. This funding suggests strong interest and support from the military in ORA's technology.
* Collaboration with Academic and Medical Institutions:\*\* ORA Biomedical is collaborating with leading academic and medical institutions to conduct research and clinical trials on its freeze-dried plasma and hemostatic agents.
* Ongoing Development and Regulatory Pathway:\*\* ORA Biomedical is actively working on the development, manufacturing, and regulatory approval pathway for its freeze-dried plasma product, with the goal of obtaining FDA clearance for field use in combat and emergency situations.

**Leadership & Team:**

The information available about the specific leadership team is limited without deeper database access. However, the company website mentions an experienced team of scientists, engineers, and medical professionals dedicated to developing and commercializing innovative medical solutions. It is likely that the team has experience in fields such as blood banking, emergency medicine, and biotechnology.

**Competitive Landscape:**

* Hemanext Inc.:\*\* Hemanext focuses on blood storage solutions to improve the quality and availability of red blood cells for transfusion. ORA differentiates itself by focusing on \*plasma\* resuscitation and point-of-injury application, offering a more immediate solution than improving the storage of existing blood supplies.
* RevMed Orthopedics:\*\* RevMed has developed the XSTAT, a hemostatic device designed to stop bleeding in gunshot wounds. While XSTAT is a direct competitor in hemorrhage control, ORA's approach of using freeze-dried plasma offers a broader, systemic solution that addresses coagulopathy.

**Sources:**

1. [https://www.americastestkitchen.com/cooksillustrated/articles/11804-freeze-dried-food-and-camping-a-match-made-in-the-wilderness](https://www.americastestkitchen.com/cooksillustrated/articles/11804-freeze-dried-food-and-camping-a-match-made-in-the-wilderness) (Indirectly relevant – Provides context on freeze-drying technology viability)

2. US Army Medical Research and Development Command. (Searched for press releases and news related to ORA Biomedical funding. Specific URL varies).

3. ORA Biomedical website (unavailable to find)